apoB has gained support as a risk marker from several recent analyses that have directly compared apoB to ~LDL-C (34,35). Grundy outlined the advantages and disadvantages of non-HDL-C and apoB and concluded that apoB is a reasonable alternative to non-HDL-C and proposed practical cutoffs (Table 2) (28). Updated prevention guidelines from the Canadian Cardiovascular Society (CCS) (4) and Canadian Diabetes Association (41) have also introduced apoB as an alternative to ~LDL-C. The CCS notes that apoB is especially useful for patients with metabolic syndrome and for following patients on lipid-lowering therapy (Table 2).
Was this article helpful?